This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Unique Technologies

Cyprotex offer a number of unique technologies either developed in-house or through our collaborators/partners.

Pharmaceutical & Biotech

eCiphr®Cardio

Synchronously beating iPS cell derived cardiomyocytes are monitored by high throughput microelectrode array (MEA) to measure whole cell electrophysiology and an ECG-like response. This technology provides a unique in vitro system for preclinical drug discovery, cardiotoxicity assessment and disease modeling.
Pharmaceutical & Biotech

eCiphr®Neuro

Primary cortical neurons are monitored by high throughput microelectrode array (MEA). The cells recapitulate many features of neurons in vivo, and enable assessment of spiking rate, burst characteristics and synchrony. This technology provides a unique in vitro system for preclinical drug discovery, neurotoxicity assessment and disease modeling.
Pharmaceutical & Biotech

CellCiphr® Premier

An extensive panel of toxicological endpoints are assessed in multiple cell types and at multiple time points using high content screening (HCS). By combining these endpoints with exposure levels (measured Cmax or predicted Cmax using Cloe® PK), the system delivers a sensitive and specific prediction of DILI (drug-induced liver injury).
Skin Sensitisation Testing

Cloe® PK, Cloe® HIA, chemPK™ and chemTox

Cyprotex have extensive expertise in physiologically based pharmacokinetic (PBPK) and quantitative structure property relationship (QSPR) modeling. We have developed our own predictive software systems which, in the case of Cloe® PK and Cloe® HIA, predict pharmacokinetic parameters from in vitro ADME and physicochemical profiling data, or in the case of chemPK™ and chemTox, predict pharmacokinetics, Ames mutagenicity, rat acute dose LD50 or aqueous solubility directly from chemical structure alone.
Pharmaceutical & Biotech

Knockout Transporter Cell-Based Assays

Cyprotex were the first company to license and validate Sigma® Life Science knockout transporter cell-based assays. The P-gp, BCRP and MRP2 single and double knockout cells are derived from a human cell line with multiple transporters expressed in a single cell and, as such, offer a physiologically relevant system for studying drug permeability and transporter interactions. The cells have several other advantages over existing in vitro systems in that they have reduced reliance on specific substrate/inhibitors and are completely devoid of activity unlike some of the knockdown systems.
Pharmaceutical & Biotech

3D Microtissues

Compared to 2D cellular models, 3D microtissues more closely mimic native tissue and allow multiple dosing over an extended exposure period. Cyprotex offer both 3D liver and cardiac tissue models for assessing drug metabolism and drug-induced toxicity.
Make enquiry
ADME Guide Tox Guide DDI Guide

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close